{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,12]],"date-time":"2025-09-12T19:31:12Z","timestamp":1757705472393},"reference-count":29,"publisher":"Japan Endocrine Society","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Endocr J"],"published-print":{"date-parts":[[2021]]},"DOI":"10.1507\/endocrj.ej20-0184","type":"journal-article","created":{"date-parts":[[2020,9,28]],"date-time":"2020-09-28T22:05:41Z","timestamp":1601330741000},"page":"145-151","source":"Crossref","is-referenced-by-count":7,"title":["Propylthiouracil-induced otitis media with anti-neutrophil cytoplasmic antibody-associated vasculitis: a case report and review of the literature"],"prefix":"10.1507","volume":"68","author":[{"given":"Marino","family":"Hiruma","sequence":"first","affiliation":[{"name":"Ito hospital, Tokyo, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoshiyuki","family":"Sasano","sequence":"additional","affiliation":[{"name":"Department of Otorhinolaryngology, St. Marianna University School of Medicine, Kanagawa, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Natsuko","family":"Watanabe","sequence":"additional","affiliation":[{"name":"Ito hospital, Tokyo, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ai","family":"Yoshihara","sequence":"additional","affiliation":[{"name":"Ito hospital, Tokyo, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Satoshi","family":"Ishii","sequence":"additional","affiliation":[{"name":"Division of Metabolism and Endocrinology, Department of Internal Medicine, St. Marianna University School of Medicine, Kanagawa, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuichiro","family":"Yaguchi","sequence":"additional","affiliation":[{"name":"Department of Otorhinolaryngology, St. Marianna University School of Medicine, Kanagawa, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jaeduk","family":"Yoshimura Noh","sequence":"additional","affiliation":[{"name":"Ito hospital, Tokyo, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kiminori","family":"Sugino","sequence":"additional","affiliation":[{"name":"Ito hospital, Tokyo, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Koichi","family":"Ito","sequence":"additional","affiliation":[{"name":"Ito hospital, Tokyo, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"386","reference":[{"key":"1","doi-asserted-by":"publisher","unstructured":"1 Okamura H, Ohtani I, Anzai T (1992) The hearing loss in Wegener\u2019s granulomatosis: relationship between hearing loss and serum ANCA. Auris Nasus Larynx 19: 1\u20136.","DOI":"10.1016\/S0385-8146(12)80195-7"},{"key":"2","doi-asserted-by":"publisher","unstructured":"2 Maguchi S, Fukuda S, Chida E, Terayama Y (2001) Myeloperoxidase-anti-neutrophil cytoplasmic antibody-associated sensorineural hearing loss. Auris Nasus Larynx 28: S103\u2013S106.","DOI":"10.1016\/S0385-8146(00)00103-6"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3 Thamprajamchit S, Jariengprasert C, Rajatanavin R (2004) Propylthiouracil-induced sensorineural hearing loss associated with anti-neutrophil cytoplasmic antibodies. Endocr Pract 10: 432\u2013437.","DOI":"10.4158\/ep.10.5.432"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4 Sano M, Kitahara N, Kunikata R (2004) Progressive bilateral sensorineural hearing loss induced by an antithyroid drug. ORL J Otorhinolaryngol Relat Spec 66: 281\u2013285.","DOI":"10.1159\/000081126"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5 Raja UY, Kumar A, Possamai V, Warner D, Barton D (2010) Drug-induced sensorineural deafness caused by antithyroid drugs: a rare side effect. J R Coll Physicians Edinb 40: 219\u2013220.","DOI":"10.4997\/JRCPE.2010.308"},{"key":"6","unstructured":"6 Harabuchi Y, Iino Y, Kishibe K, Yoshida N, Tateyama K, et al. (2013) The diagnostic criteria of otitis media with ANCA associated vasculitis (OMAAV). Otol Jpn 23: 279\u2013281 (In Japanese)."},{"key":"7","unstructured":"7 Yoshida N, Harabuchi Y, Kishibe K, Tateyama K, Morita Y, et al. (2016) The diagnostic criteria 2015 of otitis media with ANCA associated vasculitis (OMAAV) and the commentary. Otol Jpn 26: 37\u201339 (In Japanese)."},{"key":"8","unstructured":"8 Japan Otological Society (2016) Diagnosis and treatment. In: Japan Otological Society (ed) Clinical characteristics, the diagnostic criteria and management recommendation of otitis media with antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (OMAAV). Kanehara-shuppan, Japan: 30\u201365 (In Japanese)."},{"key":"9","doi-asserted-by":"crossref","unstructured":"9 Harabuchi Y, Kishibe K, Tateyama K, Morita Y, Yoshida N, et al. (2020) Clinical characteristics, the diagnostic criteria and management recommendation of otitis media with antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (OMAAV) proposed by Japan otological society. Auris Nasus Larynx. Online ahead of print.","DOI":"10.1016\/j.anl.2020.07.004"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10 Watanabe N, Narimatsu H, Noh JY, Yamaguchi T, Kobayashi K, et al. (2012) Antithyroid drug-induced hematopoietic damage: a retrospective cohort study of agranulocytosis and pancytopenia involving 50,385 patients with Graves\u2019 disease. J Clin Endocrinol Metab 97: E49\u2013E53.","DOI":"10.1210\/jc.2011-2221"},{"key":"11","doi-asserted-by":"publisher","unstructured":"11 Kobayashi S, Noh JY, Mukasa K, Kunii Y, Watanabe N, et al. (2014) Characteristics of agranulocytosis as an adverse effect of antithyroid drugs in the second or later course of treatment. Thyroid 24: 796\u2013801.","DOI":"10.1089\/thy.2013.0476"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12 Suzuki N, Noh JY, Hiruma M, Kawaguchi A, Morisaki M, et al. (2019) Analysis of antithyroid drug-induced severe liver injury in 18,558 newly diagnosed patients with Graves\u2019 disease in Japan. Thyroid 29: 1390\u20131398.","DOI":"10.1089\/thy.2019.0045"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13 Nakamura H, Noh JY, Itoh K, Fukata S, Miyauchi A, et al. (2007) Comparison of methimazole and propylthiouracil in patients with hyperthyroidism caused by Graves\u2019 disease. J Clin Endocrinol Metab 92: 2157\u20132162.","DOI":"10.1210\/jc.2006-2135"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14 Noh JY, Yasuda S, Sato S, Matsumoto M, Kunii Y, et al. (2009) Clinical characteristics of myeloperoxidase anti-neutrophil cytoplasmic antibody-associated vasculitis caused by antithyroid drugs. J Clin Endocrinol Metab 94: 2806\u20132811.","DOI":"10.1210\/jc.2008-2700"},{"key":"15","unstructured":"15 The Japan Research Committee of the Ministry of Health, Labour, and Welfare (2017) Basic and clinical practice of ANCA-associated vasculitis. In: The Japan Research Committee of the Ministry of Health, Labour, and Welfare (ed). 2017 Clinical practice guidelines of ANCA-associated vasculitis. Shindan to chiryo sya, Japan: 71\u201377 (In Japanese)."},{"key":"16","doi-asserted-by":"publisher","unstructured":"16 Sera N, Ashizawa K, Ando T, Abe Y, Ide A, et al. (2000) Treatment with propylthiouracil is associated with appearance of anti-neutrophil cytoplasmic antibody in some patients with Graves\u2019 disease. Thyroid 10: 595\u2013599.","DOI":"10.1089\/10507250050137707"},{"key":"17","unstructured":"17 Sato H, Hattori M, Fujieda M, Sugihara S, Inomata H, et al. (2000) High prevalence of anti-neutrophil cytoplasmic antibody positivity in childhood onset Graves\u2019 disease treated with propylthiouracil. J Clin Endocrinol Metab 85: 4270\u20134273."},{"key":"18","doi-asserted-by":"crossref","unstructured":"18 Gunton JE, Stiel J, Clifton-Bligh P, Wilmshurst E, McElduff A (2000) Prevalence of positive anti-neutrophil cytoplasmic antibody (ANCA) in patients receiving anti-thyroid medication. Eur J Endocrinol 142: 587.","DOI":"10.1530\/eje.0.1420587"},{"key":"19","doi-asserted-by":"crossref","unstructured":"19 Noh JY, Asari T, Hamada N, Makino F, Ishikawa N, et al. (2001) Frequency of appearance of myeloperoxidase-anti-neutrophil cytoplasmic antibody (MPO-ANCA) in Graves\u2019 disease patients treated with propylthiouracil and the relationship between MPO-ANCA and clinical manifestations. Clin Endocrinol (Oxf) 54: 651\u2013654.","DOI":"10.1046\/j.1365-2265.2001.01282.x"},{"key":"20","doi-asserted-by":"crossref","unstructured":"20 Wada N, Mukai M, Kohno M, Notoya A, Ito T, et al. (2002) Prevalence of serum anti-myeloperoxidase anti-neutrophil cytoplasmic antibodies (MPO-ANCA) in patients with Graves\u2019 disease treated with propylthiouracil and thiamazole. Endocr J 49: 329\u2013334.","DOI":"10.1507\/endocrj.49.329"},{"key":"21","unstructured":"21 Japan Otological Society (2016) Worldwide reports. In: Japan Otological Society (ed) Clinical characteristics, the diagnostic criteria and management recommendation of otitis media with antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (OMAAV). Kanehara-shuppan, Japan: 90\u2013106 (In Japanese)."},{"key":"22","unstructured":"22 Nishimura S, Sugawara K, Kobayashi Y, Yamashita Y (2018) ANCA-associated vasculitis otitis media improved by discontinuation of antithyroid drugs. Audiology Japan 61: 485 (Abstract) (In Japanese)."},{"key":"23","unstructured":"23 Suwa H, Hanai T, Hayashida R, Kobayashi M, Nakagome D, et al. (2018) A case of PTU-induced ANCA-associated otitis media treated with rituximab. Nihon Naibunpi Gakkai Zasshi 94: 93 (Abstract) (In Japanese)."},{"key":"24","doi-asserted-by":"crossref","unstructured":"24 Tanaka R, Shimojima Y, Moteki H, Kishida D, Ueno K, et al. (2018) Propylthiouracil-induced otitis media with anti-neutrophil cytoplasmic antibody-associated vasculitis. Intern Med 57: 3029\u20133033.","DOI":"10.2169\/internalmedicine.0944-18"},{"key":"25","doi-asserted-by":"crossref","unstructured":"25 Jennette JC, Falk RJ, Bacon PA, Basu N, Cid MC, et al. (2013) 2012 Revised International Chapel Hill Consensus Conference Nomenclature of Vasculitides. Arthritis Rheum 65: 1\u201311.","DOI":"10.1002\/art.37715"},{"key":"26","doi-asserted-by":"crossref","unstructured":"26 Yates M, Watts RA, Bajema IM, Cid MC, Crestani B, et al. (2016) EULAR\/ERA-EDTA recommendations for the management of ANCA-associated vasculitis. Ann Rheum Dis 75: 1583\u20131594.","DOI":"10.1136\/annrheumdis-2016-209133"},{"key":"27","doi-asserted-by":"crossref","unstructured":"27 Harigai M, Nagasaka K, Amano K, Bando M, Dobashi H, et al. (2019) 2017 Clinical practice guidelines of the Japan Research Committee of the Ministry of Health, Labour, and Welfare for Intractable Vasculitis for the management of ANCA-associated vasculitis. Mod Rheumatol 29: 20\u201330.","DOI":"10.1080\/14397595.2018.1500437"},{"key":"28","doi-asserted-by":"crossref","unstructured":"28 Harabuchi Y, Kishibe K, Tateyama K, Morita Y, Yoshida N, et al. (2017) Clinical features and treatment outcomes of otitis media with antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (OMAAV): a retrospective analysis of 235 patients from a nationwide survey in Japan. Mod Rheumatol 27: 87\u201394.","DOI":"10.1080\/14397595.2016.1177926"},{"key":"29","doi-asserted-by":"publisher","unstructured":"29 Yang J, Yao LP, Dong MJ, Xu Q, Zhang J, et al. (2017) Clinical characteristics and outcomes of propylthiouracil-induced antineutrophil cytoplasmic antibody-associated vasculitis in patients with Graves\u2019 disease: a median 38-month retrospective Cohort study from a single institution in China. Thyroid 27: 1469\u20131474.","DOI":"10.1089\/thy.2017.0468"}],"container-title":["Endocrine Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/endocrj\/68\/2\/68_EJ20-0184\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,3,6]],"date-time":"2021-03-06T03:23:54Z","timestamp":1615001034000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/endocrj\/68\/2\/68_EJ20-0184\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021]]},"references-count":29,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2021]]}},"URL":"https:\/\/doi.org\/10.1507\/endocrj.ej20-0184","relation":{},"ISSN":["0918-8959","1348-4540"],"issn-type":[{"value":"0918-8959","type":"print"},{"value":"1348-4540","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021]]}}}